Prime Medicine
Esra Camci has a Ph.D. in Biochemistry and Molecular Biology from the University of Washington. Esra has worked as a Scientist II at Prime Medicine, Inc. focusing on Genetic Hearing Loss. Prior to that, Esra was a Scientist I at Oxford Biomedica Solutions, where Esra worked on developing NGS assays for AAV-mediated gene therapies. Esra's research background includes studying aminoglycoside and cisplatin-associated hearing loss as a Postdoctoral Research Fellow at the University of Washington - School of Medicine. During their time as a Graduate Research Assistant at the University of Washington, Esra focused on genetics and developmental biology underlying facial dysmorphology.
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.